Returning for its fifth year, the Antigen-Specific Immune Tolerance Summit will lean into the industry’s key challenges of understanding the mechanisms inducing tolerance, characterizing driver antigens of disease, monitoring immune response, and accelerating durable therapies into the clinic.

This is your comprehensive guide to define your drug development strategy for 2022 and delve into the therapeutic opportunity held by the next generation of antigen-specific immunotherapies. Expect to be involved in interactive discussions on:

• Examining the mechanisms underlying immune tolerance to drive antigen and epitope discovery with insights from the NIH, Vaccibody, and Imcyse
• Leveraging immune biomarkers and explore immune tolerance in diabetes with Novo Nordisk, COUR Pharmaceuticals, and Diamyd Medical
• Exploring the diversity of technologies and platforms for antigen delivery withToleranzia, Idogen AB, and AnTolRx, Inc
• Optimizing clinical durability and efficacy of antigen-specific immunotherapies with insights from WORG Pharmaceuticals, and Cellerys

Uniting 80+ industry experts to discuss cutting-edge content exploring the latest advances in the field of antigen-specific immune tolerance, this is a conversation not to miss.

Take a look at the event guide here.